Protego Biopharma focuses on the discovery and development of small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are building upon our expertise in the proven pharmacological chaperone approach exemplified by tafamidis, the first marketed disease modifying agent for the treatment of a systemic amyloidosis. The incorporation of the latest advances in biology, chemical biology, biomarkers, structure biology, computation into our approach allows us to expand our disease scope and generate the best therapeutics possible. Our expertise allows us to focus upon generating the key preclinical data that will have clinical translation within the pharmacological chaperone approach. We have assembled a proven team of experts in discovery and development of small molecule pharmacological chaperones and protein homeostasis modulators. This team has joined forces with world-class investors and collaborators who embrace our mission.